| Annual · values | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -244.50 M USD | -206.89 M USD | — | — |
| Depreciation & Amortization | 36.69 M USD | 31.15 M USD | — | — |
| Stock-Based Compensation | — | — | — | — |
| Capital Expenditures | -52.69 M USD | -295.31 M USD | — | — |
| Cash Flow from Investing | — | — | — | — |
| Cash Flow from Financing | — | — | — | — |
| Dividends Paid | — | — | — | — |
| Stock Buybacks | — | — | — | — |
| Free Cash Flow | -239.52 M USD | -472.48 M USD | — | — |
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.